Rainbow Coral Corp. RBCC Archives - Page 2 of 3

WednesdayApr 24, 2013 9:04 am

Rainbow Coral Corp. (RBCC) Takes International Approach to Finding Potentially Lucrative Licensing Opportunities

In the goal of increasing market opportunities for its biotech innovations, Rainbow Coral is now looking for new overseas targets that could benefit from adding licenses for the drug delivery protocols that its joint venture partner, TheraKine, has developed. According to some experts, the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015. TheraKine is a leader in this space, having developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery. These technologies promise to lower drug concentrations and significantly reduced risk of drug toxicity.…

MondayApr 22, 2013 10:41 am

Rainbow Coral Corp. (RBCC) and the New World of Pharmacogenomics

Immunotherapy and stem cell technology represent two of the hottest fields in medical science today. Although there is still much research to be done, immunotherapy is seen as the ultimate weapon against some of the most intractable diseases, essentially having the best potential to hunt out and destroy bad cells. And stem cell technology is seen as the best hope for regenerating the body, essentially building more good cells. But there’s a third less known but no less important component to the future of modern medicine. It’s called pharmacogenomics, a field of study derived from the Human Genome Project. The…

MondayApr 15, 2013 8:53 am

Rainbow Coral Corp. (RBCC) Subsidiary’s Negotiations with Leading Genetic Testing Lab Nearly Complete

Rainbow BioSciences, the biotech division of Rainbow Coral, this morning told investors that it is nearing a definitive agreement with a leading, Texas-based genetic testing laboratory. One of the fastest-growing segments of the global biotech industry, the genetic testing sector is projected to reach $2.2 billion by 2017. The laboratory in negotiations with RBCC specializes in the cutting-edge science of pharmacogenomics, a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. Pharmacogenomics could be the key to truly personalized medicine,…

MondayApr 08, 2013 9:12 am

Rainbow Coral Corp. (RBCC) Expands Focus in Booming $232 Billion Personalized Medicine Market

Today before the opening bell, Rainbow Coral announced that its biotech subsidiary, Rainbow BioSciences, will be targeting new innovations in the growing field of companion diagnostics. Ripe for expansion, the U.S. personalized medicine market is expected to grow to as much as $452 billion by 2015. Companion diagnostics is one of the fastest-growing fields in the market; it alone could total $42 billion in size by 2015, according to industry analysts TriMarkPublications.com. The key to ongoing rapid growth will be innovation. Companion diagnostics is the use of genetic variation to chart different patient responses to specific drugs or biologic agents…

TuesdayApr 02, 2013 8:53 am

Rainbow Coral Corp. (RBCC) Launches New Website, Highlights Impressive Deal Flow

Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp., revealed a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market. The new website replaces the prior version and can be found at www.rainbowbiosciences.com. The revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to…

WednesdayMar 20, 2013 8:39 am

Rainbow Coral Corp. (RBCC) Signs JV Agreement with Cutting-Edge Drug Delivery Company

Today before the opening bell, the biotech division of Rainbow Coral announced it has formed a Joint Venture (JV) with TheraKine to solve the problems presented by systemic drug delivery. The new JV is an extension of the company’s bold expansion into the $60 billion global drug delivery market. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery,…

WednesdayMar 13, 2013 9:05 am

Rainbow Coral Corp. (RBCC) to Participate in the Growing $60 Billion Drug Delivery Market

The next generation of advanced pharmaceutical technologies holds great potential and could fuel extraordinary growth in the $60 billion global drug delivery market. Rainbow Coral’s biotech subsidiary, Rainbow BioSciences, aims to be right in the middle of the action. Some pharmaceutical giants believe new drug delivery methods will serve as a crucial growth generator, and new innovations are constantly taking place across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare, and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system. Rainbow Coral…

WednesdayMar 06, 2013 7:52 am

Rainbow Coral Corp. (RBCC) Nears Completion of Strategic Partnership with Trailblazing Pharmacogenomics Lab

Rainbow Coral recognizes genetic testing as “the future of medicine,” and this biotech small-cap company has every intention of securing its position in the burgeoning sector by expanding and honing its genetic exploration initiatives. Reflecting this mission, RBCC today said that in the next few weeks it will finalize its partnership with a pioneering genome-mapping facility based in Houston, Texas, to focus on cutting-edge pharmacogenomics, a field of study resulting from the Human Genome Project, which aims to assist medical professionals assess genetic variations in patients in order to create optimal drug treatment plans. “This is the next evolution in…

MondayMar 04, 2013 8:09 am

Rainbow Coral Corp. (RBCC) Engages QualityStocks Investor Relations Services

Rainbow Coral just announced that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts. The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral…

WednesdayFeb 27, 2013 7:41 am

Rainbow Coral Corp. (RBCC) Pursues JV Involving Revolutionary Breakthrough in $60 Billion Drug Delivery Market

Rainbow Coral today announced that its biotech division, Rainbow BioSciences, is currently in talks to help develop and market a revolutionary, sustained-release drug delivery platform that could soon enable safer delivery of biologic agents and small molecules, while also increasing efficacy and convenience to a whole new level. Specifically, a joint venture agreement with a privately held drug delivery company developing the novel technology is on the table. The local delivery platform is being developed to address the issues posed by systemic drug delivery, including oral and IV delivery. Often systemically delivered drugs can’t reach sufficient concentrations in target organs…

Site Search

Company Search

Tag: Rainbow Coral Corp. RBCC